Startup profile for vVARDIS: latest funding, latest known valuation, total disclosed funding, investors, status, sources, and why the company is interesting. Part of the Venture Capital Tracker startup directory.

Startup profile · funding coverage

vVARDIS funding, valuation and investors

Swiss dental-medtech company selling clinician-applied Curodont peptide products for early-stage tooth decay; NYSE: VVVV since November 13, 2026.

Verified company research · funding, investors and latest developments

Keep track of vVARDIS

Save this profile to your VCT watchlist for a quick return.

View watchlist

Funding, valuation & investors

Answer-first snapshot

Latest funding

Not publicly disclosed

Latest known valuation

Not publicly disclosed

Total disclosed equity funding

Not publicly disclosed

Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.

Current status

public

public · Zug, Switzerland

Source links not recorded Last verified: 2026-11-16

Overview

Founded by dentist sisters Drs. Haley and Goly Abivardi and based in Zug, Switzerland, vVARDIS commercializes non-invasive treatments for early enamel lesions under the Curodont brand. Its principal US product Curodont Repair Fluoride Plus is applied by trained dental clinicians rather than sold as a direct consumer remedy.

Shares priced at $18 in a Nov 13, 2026 initial public offering, yielding ~$175M gross before offering costs, and were listed on the NYSE as VVVV; the legal offering close was only scheduled for Nov 16. Its prospectus documents significant reliance on distributor Henry Schein and operating losses.

Earlier GP-issued OrbiMed releases described $35M Feb 2025 financing and $50M July 2025 additional funding; do not assume both were venture equity.

Why vVARDIS is interesting

vVARDIS priced 9,722,223 Class A shares at $18 on Nov 13, 2026 (~$175M gross IPO) after an indicated $21–$24 range. Its Curodont product is already distributed to US dentists through Henry Schein. Crucial distinction: NYSE trading began Nov 13, while IPO legal settlement was scheduled for about Nov 16 and unconfirmed at research time. OrbiMed's two 2025 financings totaled $85M but their debt/equity composition should not be invented.

Product & use cases

Product: Curodont Repair Fluoride Plus, an in-office peptide/fluoride treatment designed for noncavitated early enamel carious lesions (including white-spot lesions). Buyer: dental practice or group through distributors, notably exclusive US partner Henry Schein; patient receives the treatment but is not necessarily vVARDIS's direct customer. Source-backed, illustrative dentist visit (not hands-on testing): (1) clinician diagnoses an early lesion using examination/radiographs and assesses whether drilling or repair is appropriate; (2) educates patient and prepares a clean dry site; (3) readies the Curodont Unit A sponge with Unit B liquid, and treats enamel per the professional IFU including brief etching; (4) squeezes the saturated sponge on/near the lesion, without a drill or filling; (5) instructs no eating, drinking or rinsing for 30 minutes and follows up to assess mineralization and progression. Use only the manufacturer's current clinical instructions, not this description as patient self-care instructions. It cannot be assumed effective for deep cavitated decay, all patients or every tooth surface. Product is distributed through dental channels; no verified standard patient or clinic unit price is published here.

  • Dental offices evaluating early-lesion enamel remineralization treatments without drilling; only eligible noncavitated caries.
  • Patients with early tooth decay discussing available chairside treatment options; use professional diagnosis and clinician judgment.
  • Investors assessing a fast-growing product business with high distributor concentration, significant losses and a dual-class post-IPO governance structure.
  • Dental groups comparing traditional preventive fluoride varnish, resin infiltration and restorative drilling against clinician-applied peptide treatment.

Key facts

  • Issuer announcement Nov 13 2026: 9,722,223 IPO shares × $18 = $175,000,014 gross before fees; additional 1,458,333 underwriter option shares not included. NYSE ticker VVVV. Legal close expected around Nov 16, subject to conditions.
  • IPO price was below the $21–$24 preliminary range; an IPO price is not a transaction valuation and does not itself prove eventual legal proceeds paid.
  • 2025 issuer disclosures: OrbiMed initial $35M financing closed February; additional $50M closed July, $85M combined. Instruments and refinancing component must not be assumed to be entirely new equity.
  • Official Curodont Repair Fluoride Plus professional instructions restrict use to trained in-office providers for early caries; advanced cavitated lesions may still require conventional restoration.
  • FY2025 issuer filing figures: ~$30.2M revenue versus ~$56.4M net loss; Henry Schein accounted for ~72% of sales in 2025 and ~90% in H1 2026, exposing customer concentration. F-1 disclosures, not unaudited marketing claims.
  • Company announced Apollo-managed funds' minority investment in April 2026; precise invested amount and transaction valuation undisclosed despite issuer's 'unicorn' description.

Competitive landscape

Edge: A branded, clinician-administered peptide formulation designed to address lesion depth and preserve enamel, integrated with professional dental workflows through Henry Schein distribution. The product's specific claims depend on the population and study; it does not eliminate conventional fillings for advanced lesions. Company adoption figures are not causal clinical efficacy or audited patient outcomes.

Primary evidence: vVARDIS November 13 2026 issuer IPO statement establishes $18/share and share count, but not the legal settlement on November 16. The current company site independently states NYSE:VVVV listed. Clinical workflow is taken from the company's professional product documentation. The 2025 annual/2026 first-half revenue, net-loss and Henry Schein concentration figures are from disclosed F-1/A figures summarized by filing-based Cityfort and should be refreshed against definitive SEC filing before high-stakes valuation analysis. Independent competitor pages may use older November 6/12 offering share counts and $21–$24 preliminary price: the finalized November 13 issue supersedes them. Pricing to dentists/patients and reimbursed economics not publicly established by the sources reviewed.

  • DMG Icon resin infiltration direct

    A professional minimally invasive method for selected early lesions; different resin-based mechanism and protocols.

  • Fluoride varnish alternative

    Established preventive/remineralizing professional treatment; economics and evidence depend on lesion and patient risk.

  • Silver diamine fluoride alternative

    Can arrest caries in suitable patients but often stains treated lesions; unlike Curodont's tooth-colour positioning.

  • Conventional composite restorations incumbent

    Necessary for many cavitated/progressed lesions; removes tooth structure and is not an equivalent early-lesion intervention.

Notable stories

Market / IPO context

Ticker: VVVV (NYSE)

IPO status: public

IPO date: 2026-11-13

Note: Nov 13 2026 IPO priced $18/share, 9,722,223 Class A shares (~$175.0M gross). Underwriters' option for 1,458,333 shares excluded. NYSE trading began November 13; legal closing scheduled on/about Nov 16 and not independently confirmed as completed. Do not infer precise post-money value from simple class B share count because economic/voting rights differ.

Editorial / static context — not a live quote.

By Venture Capital Tracker

Last updated:

Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.